Biorestorative Therapies Inc Financials

BRTX

Source SEC Filings (10-K/10-Q) Updated Sep 30, 2025 Currency USD FYE December

This page shows Biorestorative Therapies Inc (BRTX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 16 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 59/100

Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Biorestorative Therapies Inc has an operating margin of -2881.6%, meaning the company retains $-2882 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -10439.5% the prior year.

Growth

100

Biorestorative Therapies Inc's revenue surged 175.0% year-over-year to $401K, reflecting rapid business expansion. This strong growth earns a score of 100/100.

Leverage

Biorestorative Therapies Inc carries a low D/E ratio of 0.44, meaning only $0.44 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 95/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

With a current ratio of 2.97, Biorestorative Therapies Inc holds $2.97 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 99/100.

Cash Flow

While Biorestorative Therapies Inc generated -$8.2M in operating cash flow, capex of $106K consumed most of it, leaving -$8.3M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.

Piotroski F-Score Weak

3/9

Biorestorative Therapies Inc passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 efficiency signals pass.

Earnings Quality Low Quality

0.92x

For every $1 of reported earnings, Biorestorative Therapies Inc generates $0.92 in operating cash flow (-$8.2M OCF vs -$9.0M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-18.8x

Biorestorative Therapies Inc earns $-18.8 in operating income for every $1 of interest expense (-$11.6M vs $616K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Revenue

$401K

YoY+175.0%

5Y CAGR+25.3%

10Y CAGR-0.4%

Biorestorative Therapies Inc generated $401K in revenue in fiscal year 2024. This represents an increase of 175.0% from the prior year.

EBITDA

-$11.4M

YoY+24.5%

Biorestorative Therapies Inc's EBITDA was -$11.4M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 24.5% from the prior year.

Free Cash Flow

-$8.3M

YoY-26.3%

Biorestorative Therapies Inc generated -$8.3M in free cash flow in fiscal year 2024, representing cash available after capex. This represents a decrease of 26.3% from the prior year.

Net Income

-$9.0M

YoY+13.8%

Biorestorative Therapies Inc reported -$9.0M in net income in fiscal year 2024. This represents an increase of 13.8% from the prior year.

EPS (Diluted)

$-1.16

YoY+53.0%

Biorestorative Therapies Inc earned $-1.16 per diluted share (EPS) in fiscal year 2024. This represents an increase of 53.0% from the prior year.

Cash & Debt

$548K

YoY-38.0%

5Y CAGR+218.8%

10Y CAGR+19.6%

Biorestorative Therapies Inc held $548K in cash against $0 in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

YoY+47.0%

Biorestorative Therapies Inc had 7M shares outstanding in fiscal year 2024. This represents an increase of 47.0% from the prior year.

Gross Margin

93.0%

YoY-7.0pp

10Y CAGR+44.4pp

Biorestorative Therapies Inc's gross margin was 93.0% in fiscal year 2024, indicating the percentage of revenue retained after direct costs. This is down 7.0 percentage points from the prior year.

Operating Margin

-2881.6%

YoY+7557.9pp

5Y CAGR+3604.6pp

10Y CAGR-1698.3pp

Biorestorative Therapies Inc's operating margin was -2881.6% in fiscal year 2024, reflecting core business profitability. This is up 7557.9 percentage points from the prior year.

Net Margin

-2239.3%

YoY+4905.9pp

5Y CAGR+9028.4pp

10Y CAGR-896.1pp

Biorestorative Therapies Inc's net profit margin was -2239.3% in fiscal year 2024, showing the share of revenue converted to profit. This is up 4905.9 percentage points from the prior year.

Return on Equity

N/A

R&D Spending

$5.3M

YoY+32.6%

5Y CAGR+25.4%

10Y CAGR+14.1%

Biorestorative Therapies Inc invested $5.3M in research and development in fiscal year 2024. This represents an increase of 32.6% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$106K

YoY-37.9%

5Y CAGR+24.4%

10Y CAGR-4.5%

Biorestorative Therapies Inc invested $106K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 37.9% from the prior year.

BRTX Income Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Revenue	$401K+175.0%	$146K+21.7%	$120K+160.4%	$46K-40.3%	$77K-40.8%	$130K
Cost of Revenue	$28K	N/A	N/A	N/A	N/A	N/A
Gross Profit	$373K+155.8%	$146K	N/A	N/A	N/A	N/A
R&D Expenses	$5.3M+32.6%	$4.0M+14.8%	$3.5M+381.9%	$729K-16.9%	$877K-49.1%	$1.7M
SG&A Expenses	$6.6M-41.9%	$11.3M-27.3%	$15.6M-39.2%	$25.6M+1334.2%	$1.8M-61.2%	$4.6M
Operating Income	-$11.6M+24.1%	-$15.2M+19.8%	-$19.0M+27.9%	-$26.3M-855.9%	-$2.8M+67.4%	-$8.4M
Interest Expense	$616K+11.5%	$552K+4640.7%	$12K+100.6%	-$1.8M	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$9.0M+13.8%	-$10.4M+21.2%	-$13.2M+70.2%	-$44.3M-293.0%	-$11.3M+23.0%	-$14.6M
EPS (Diluted)	$-1.16+53.0%	$-2.47+32.3%	$-3.65	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Revenue	$12K-96.1%	$303K+1113.2%	$25K-42.3%	$43K-51.4%	$89K+154.6%	$35K+81.3%	$19K-37.1%	$31K
Cost of Revenue	$11K+21.1%	$9K+200.1%	$3K-84.1%	$18K+181.1%	$6K	N/A	N/A	N/A
Gross Profit	$1K-99.6%	$295K+1233.4%	$22K-44.7%	$40K-51.6%	$83K+136.0%	$35K	N/A	$31K
R&D Expenses	$2.6M+16.6%	$2.2M+29.8%	$1.7M+23.9%	$1.4M-4.9%	$1.5M+37.4%	$1.1M-2.9%	$1.1M+34.6%	$810K
SG&A Expenses	$1.1M-18.8%	$1.4M-55.9%	$3.1M+131.3%	$1.3M+22.7%	$1.1M-64.4%	$3.1M+43.6%	$2.1M-7.5%	$2.3M
Operating Income	-$3.7M-12.2%	-$3.3M+31.2%	-$4.8M-78.7%	-$2.7M-9.0%	-$2.5M+39.9%	-$4.1M-27.6%	-$3.2M-3.7%	-$3.1M
Interest Expense	$58K-21.9%	$74K-26.1%	$100K-16.0%	$119K-32.4%	$176K+8.2%	$163K-56.8%	$376K+510.1%	$62K
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$3.0M-14.4%	-$2.7M+50.3%	-$5.3M-226.4%	-$1.6M+59.4%	-$4.0M-81.2%	-$2.2M+3.5%	-$2.3M-148.3%	$4.8M
EPS (Diluted)	$-0.33-10.0%	$-0.30+53.1%	$-0.64-220.0%	$-0.20+60.0%	$-0.50-51.5%	$-0.33-161.1%	$0.54+38.5%	$0.39

BRTX Balance Sheet

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Total Assets	$12.3M-2.6%	$12.6M-23.3%	$16.4M-26.8%	$22.5M+416.5%	$4.3M+196.5%	$1.5M
Current Assets	$11.1M-2.2%	$11.4M-24.7%	$15.1M-29.5%	$21.5M+573.6%	$3.2M+4528.1%	$69K
Cash & Equivalents	$548K-38.0%	$884K-48.4%	$1.7M-91.8%	$21.0M+586.1%	$3.1M+184071.3%	$2K
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$188K+876.2%	$19K+20.6%	$16K+220.0%	$5K-70.6%	$17K-46.9%	$32K
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$3.7M+43.8%	$2.6M-57.6%	$6.1M-47.4%	$11.7M+105.5%	$5.7M-60.1%	$14.2M
Current Liabilities	$3.7M+43.8%	$2.6M-56.4%	$6.0M+1544.2%	$364K-65.2%	$1.0M-92.4%	$13.7M
Long-Term Debt	N/A	N/A	N/A	$250K	N/A	N/A
Total Equity	$8.5M-14.7%	$10.0M-2.8%	$10.3M-4.6%	$10.8M+909.8%	-$1.3M+89.6%	-$12.8M
Retained Earnings	-$155.7M-6.1%	-$146.7M-7.6%	-$136.3M-1.6%	-$134.1M-49.3%	-$89.8M-14.3%	-$78.6M

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Total Assets	$5.6M-33.7%	$8.5M-17.5%	$10.3M-15.9%	$12.3M-23.8%	$16.1M-10.2%	$18.0M+42.3%	$12.6M-8.6%	$13.8M
Current Assets	$4.7M-38.0%	$7.6M-18.8%	$9.4M-16.1%	$11.1M-25.7%	$15.0M-10.5%	$16.8M+47.2%	$11.4M-9.6%	$12.6M
Cash & Equivalents	$602K-61.3%	$1.6M+26.6%	$1.2M+124.3%	$548K-75.7%	$2.3M+94.6%	$1.2M+30.8%	$884K-63.7%	$2.4M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$13K-10.7%	$15K-40.0%	$25K-86.7%	$188K+587.6%	$27K-21.7%	$35K+81.3%	$19K-50.9%	$39K
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$3.4M-6.4%	$3.7M-12.2%	$4.2M+11.6%	$3.7M-29.5%	$5.3M+54.3%	$3.4M+32.2%	$2.6M-14.2%	$3.0M
Current Liabilities	$3.4M-6.4%	$3.7M-12.2%	$4.2M+11.6%	$3.7M-29.5%	$5.3M+54.3%	$3.4M+32.2%	$2.6M-13.0%	$3.0M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$2.2M-54.5%	$4.8M-21.1%	$6.1M-28.0%	$8.5M-21.0%	$10.8M-25.5%	$14.5M+45.0%	$10.0M-7.0%	$10.8M
Retained Earnings	-$166.7M-1.9%	-$163.7M-1.6%	-$161.0M-3.4%	-$155.7M-1.8%	-$153.0M-2.7%	-$148.9M-1.5%	-$146.7M-1.6%	-$144.4M

BRTX Cash Flow Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Operating Cash Flow	-$8.2M-28.0%	-$6.4M-8.7%	-$5.9M-77.6%	-$3.3M-69.5%	-$2.0M+71.6%	-$6.9M
Capital Expenditures	$106K-37.9%	$171K-35.5%	$265K+765.1%	$31K	N/A	$36K
Free Cash Flow	-$8.3M-26.3%	-$6.6M-6.8%	-$6.2M-83.8%	-$3.4M	N/A	-$7.0M
Investing Cash Flow	$515K-84.2%	$3.3M+124.3%	-$13.4M-43607.5%	-$31K	N/A	-$36K
Financing Cash Flow	$7.4M+214.2%	$2.3M	N/A	$21.3M+324.1%	$5.0M-26.5%	$6.8M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Operating Cash Flow	-$2.9M-7.7%	-$2.7M+3.1%	-$2.8M-18.4%	-$2.3M-25.9%	-$1.9M+19.5%	-$2.3M-46.0%	-$1.6M-34.6%	-$1.2M
Capital Expenditures	$0	$0-100.0%	$36K+192.7%	$12K	N/A	N/A	$70K+486.1%	$12K
Free Cash Flow	-$2.9M-7.7%	-$2.7M+4.3%	-$2.8M-19.3%	-$2.4M	N/A	N/A	-$1.7M-39.2%	-$1.2M
Investing Cash Flow	$2.0M-6.3%	$2.1M-9.9%	$2.4M+54.4%	$1.5M-48.5%	$3.0M+160.3%	-$4.9M-5711.5%	-$85K-297.0%	-$21K
Financing Cash Flow	-$49K-105.6%	$888K-18.7%	$1.1M+965.1%	-$126K-883.5%	-$13K-100.2%	$7.5M+8950.5%	$83K-95.5%	$1.9M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

BRTX Financial Ratios

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Gross Margin	93.0%-7.0pp	100.0%	N/A	N/A	N/A	N/A
Operating Margin	-2881.6%+7557.9pp	-10439.5%+5398.6pp	-15838.1%+41352.9pp	-57191.0%-53616.9pp	-3574.1%+2912.0pp	-6486.2%
Net Margin	-2239.3%+4905.9pp	-7145.2%+3891.8pp	-11037.0%+85274.5pp	-96311.5%-81671.7pp	-14639.9%-3372.2pp	-11267.6%
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-73.1%+9.5pp	-82.6%-2.1pp	-80.5%+116.9pp	-197.3%+62.0pp	-259.3%+739.6pp	-998.9%
Current Ratio	2.97-1.4	4.37+1.8	2.53-56.5	59.01+56.0	3.05+3.0	0.01
Debt-to-Equity	0.44+0.2	0.26-0.3	0.60+0.6	0.02+4.3	-4.26-3.2	-1.11
FCF Margin	-2078.9%+2448.7pp	-4527.6%+629.6pp	-5157.2%+2148.4pp	-7305.6%	N/A	-5349.5%

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Gross Margin	10.4%-86.7pp	97.1%+8.8pp	88.4%-3.9pp	92.3%-0.4pp	92.7%-7.3pp	100.0%	N/A	100.0%
Operating Margin	-31432.3%-30342.5pp	-1089.8%+18140.4pp	-19230.1%-13017.3pp	-6212.8%-3442.0pp	-2770.8%+8969.9pp	-11740.7%+4946.7pp	-16687.5%-6575.3pp	-10112.2%
Net Margin	-25748.1%-24872.3pp	-875.8%+20483.4pp	-21359.2%-17580.6pp	-3778.6%+742.8pp	-4521.4%+1830.8pp	-6352.2%+5585.6pp	-11937.8%-27469.6pp	15531.8%
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	44.3%
Return on Assets	-53.8%-22.6pp	-31.2%+20.5pp	-51.7%-38.4pp	-13.3%+11.7pp	-25.0%-12.6pp	-12.4%+5.9pp	-18.3%-52.8pp	34.5%
Current Ratio	1.37-0.7	2.07-0.2	2.24-0.7	2.97+0.2	2.82-2.0	4.86+0.5	4.37+0.2	4.20
Debt-to-Equity	1.56+0.8	0.76+0.1	0.68+0.2	0.44-0.1	0.49+0.3	0.24-0.0	0.26-0.0	0.28
FCF Margin	-24585.9%-23697.7pp	-888.2%+10372.5pp	-11260.7%-5809.8pp	-5451.0%	N/A	N/A	-8590.6%-4709.9pp	-3880.7%

Similar Companies

Aptorum Group Ltd APM

$6.4M

Xtl Biopharmaceu XTLB

$8.4M

Briacell Therapeutics Corp BCTX

$25.3M

Biovie Inc BIVI

$9.6M

Biomx Inc PHGE

$9.8M

Frequently Asked Questions

What is Biorestorative Therapies Inc's annual revenue?

Biorestorative Therapies Inc (BRTX) reported $401K in total revenue for fiscal year 2024. This represents a 175.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Biorestorative Therapies Inc's revenue growing?

Biorestorative Therapies Inc (BRTX) revenue grew by 175% year-over-year, from $146K to $401K in fiscal year 2024.

Is Biorestorative Therapies Inc profitable?

No, Biorestorative Therapies Inc (BRTX) reported a net income of -$9.0M in fiscal year 2024, with a net profit margin of -2239.3%.

What is Biorestorative Therapies Inc's earnings per share (EPS)?

Biorestorative Therapies Inc (BRTX) reported diluted earnings per share of $-1.16 for fiscal year 2024. This represents a 53.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

What is Biorestorative Therapies Inc's EBITDA?

Biorestorative Therapies Inc (BRTX) had EBITDA of -$11.4M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

What is Biorestorative Therapies Inc's gross margin?

Biorestorative Therapies Inc (BRTX) had a gross margin of 93.0% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.

What is Biorestorative Therapies Inc's operating margin?

Biorestorative Therapies Inc (BRTX) had an operating margin of -2881.6% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.

What is Biorestorative Therapies Inc's net profit margin?

Biorestorative Therapies Inc (BRTX) had a net profit margin of -2239.3% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.

What is Biorestorative Therapies Inc's free cash flow?

Biorestorative Therapies Inc (BRTX) generated -$8.3M in free cash flow during fiscal year 2024. This represents a -26.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Biorestorative Therapies Inc's operating cash flow?

Biorestorative Therapies Inc (BRTX) generated -$8.2M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Biorestorative Therapies Inc's total assets?

Biorestorative Therapies Inc (BRTX) had $12.3M in total assets as of fiscal year 2024, including both current and long-term assets.

What are Biorestorative Therapies Inc's capital expenditures?

Biorestorative Therapies Inc (BRTX) invested $106K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.

How much does Biorestorative Therapies Inc spend on research and development?

Biorestorative Therapies Inc (BRTX) invested $5.3M in research and development during fiscal year 2024.

How many shares does Biorestorative Therapies Inc have outstanding?

Biorestorative Therapies Inc (BRTX) had 7M shares outstanding as of fiscal year 2024.

What is Biorestorative Therapies Inc's current ratio?

Biorestorative Therapies Inc (BRTX) had a current ratio of 2.97 as of fiscal year 2024, which is generally considered healthy.

What is Biorestorative Therapies Inc's debt-to-equity ratio?

Biorestorative Therapies Inc (BRTX) had a debt-to-equity ratio of 0.44 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Biorestorative Therapies Inc's return on assets (ROA)?

Biorestorative Therapies Inc (BRTX) had a return on assets of -73.1% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is Biorestorative Therapies Inc's cash runway?

Based on fiscal year 2024 data, Biorestorative Therapies Inc (BRTX) had $548K in cash against an annual operating cash burn of $8.2M. This gives an estimated cash runway of approximately 1 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Biorestorative Therapies Inc's Piotroski F-Score?

Biorestorative Therapies Inc (BRTX) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Biorestorative Therapies Inc's earnings high quality?

Biorestorative Therapies Inc (BRTX) has an earnings quality ratio of 0.92x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Biorestorative Therapies Inc cover its interest payments?

Biorestorative Therapies Inc (BRTX) has an interest coverage ratio of -18.8x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Biorestorative Therapies Inc?

Biorestorative Therapies Inc (BRTX) scores 59 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.